Revvity (RVTY) Q1 FY26 earnings call

Revvity delivered strong Q1 FY26 results, exceeding expectations for organic growth, operating margins, and EPS, driven by robust performance in reproductive health and early signs of improvement in pharma/biotech and academic end markets. The company announced a strategic divestiture of its China immunodiagnostics business, aiming to improve its financial profile and focus resources on higher-return opportunities, which is expected to enhance future organic growth and operating margins. Significant software innovations and internal AI adoption are also underway to drive long-term growth and e